Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen.
He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the immune system.